Videos

A panelist discusses how they would communicate these comparative study results to patients by explaining that both enzalutamide and darolutamide effectively control metastatic prostate cancer when added to hormone therapy while emphasizing that darolutamide may cause fewer central nervous system adverse effects like fatigue and cognitive changes, helping patients understand the potential benefits and tradeoffs to make a treatment decision that best fits their individual situation and preferences.

A panelist discusses how the outcomes of this study broadly align with real-world treatment patterns and clinical experiences, where enzalutamide and darolutamide both demonstrate efficacy in metastatic hormone-sensitive prostate cancer (mHSPC), although practical considerations such as darolutamide’s more favorable central nervous system (CNS) toxicity profile and enzalutamide’s longer clinical experience often influence prescribing decisions based on individual patient characteristics and comorbidities

Paul E. Dato, MD, discusses how when selecting abiraterone for metastatic hormone-sensitive prostate cancer patients, there are 3 formulations to consider: standard, generic, and micronized versions, with considerations for bioavailability, fasting requirements, and patient adherence.

Investigators found that benefits of treatments that are observed in trials also appear in the real world.

Paul E. Dato, MD, discusses how a 69-year-old Black man presented with metastatic hormone-sensitive prostate cancer, showing symptoms of fatigue, nocturia, back pain, and weight loss, with initial treatment including androgen deprivation therapy and abiraterone acetate.

Panelists discuss how specific tumor characteristics, such as papillary architecture and presence of carcinoma in situ, guide risk-adapted treatment decisions in non–muscle-invasive bladder cancer.

Panelists discuss how precise risk stratification in non–muscle-invasive bladder cancer enables physicians to tailor treatment and surveillance strategies based on individual patient risk profiles.

The trial has enrolled 201 patients with localized prostate cancer to date.

The CR rate was 71% in patients with BCG-unresponsive NMIBC with CIS with or without papillary disease.

"It’s a very good time to be taking care of patients with bladder cancer," says Joshua J. Meeks, MD, PhD.

“In this well-selected patient population, it is possible to treat with systemic therapy alone," says John L. Gore, MD, MS.

“I truly think genetic testing should be incorporated as a part of daily care in prostate cancer,” says Joy Maulik, CRNP.

Hear from 5 experts as they recap some of the top data from this year's AUA.

Grace Khaner and Melissa A. Laudano, MD, share their thoughts on the potential for expanding the use of vibegron early in treatment for OAB.

DiBianco discusses findings from the Better Lithotripsy and Ureteroscopy Evaluation of Stenting trial.

“[These are] very good numbers for these patients who otherwise would undergo a radical cystectomy," says Félix Guerrero-Ramos, MD, PhD, FEBU.

Panelist discusses how benign prostatic hyperplasia (BPH) and its treatments impact men’s sexual health, emphasizing the importance of balancing symptom relief with sexual function preservation, and how patient concerns, along with treatment advancements like aqua ablation, have simplified decision-making in clinical practice.

The SOUL study is assessing patient-reported outcomes and unplanned health care utilization among patients who had stent placement vs stent omission after ureteroscopy.

“I think the best thing about these guidelines is their actual existence,” says Karyn S. Eilber, MD.

"To me, the key take-home is that the benefits that we see in clinical trials, we actually can replicate in the real world," says Stephen J. Freedland, MD.

A panelist discusses how these comparative results could influence clinical decision-making by suggesting potentially different magnitudes of benefit between enzalutamide and darolutamide depending on disease volume, with the treatment effect differences possibly being more pronounced in high-volume disease patients, although individual patient factors should still guide personalized therapy selection.

A panelist discusses how the findings in the docetaxel-naive population show distinct differences in treatment efficacy, with potentially greater benefits observed for certain androgen receptor pathway inhibitors, which suggests clinicians should consider these differential outcomes when sequencing therapies for patients with metastatic hormone-sensitive prostate cancer (mHSPC) who have not previously received chemotherapy.

“It is likely that more and more, these newer agents are going to play earlier and more central roles in the early treatment of BCG-unresponsive disease," says Shreyas S. Joshi, MD, MPH.

“It's going to be an important time for US urologists to identify that this is becoming the standard of care," says Joshua J. Meeks, MD, PhD.

Shay Rajavel, MS3, shares details on an AUA 2025 presentation on CO2 gas embolism during laparoscopic surgery.

Kevin C. Zorn, MD, FRCSC, FACS, recaps the AUA 2025 session, “State-of-the-Art Lecture: Preservation of Ejaculatory Function with BPH Treatments."

Neal D. Shore, MD, FACS, shares the background and key findings from the phase 3 CREST trial, exploring sasanlimab plus BCG for BCG-naive NMIBC.

Vitaly Margulis, MD, shares his insights on initial data from the phase 3 ENLIGHTED trial.